An effective and additional treatment to fight cancer.

  • What's Hyperthermia?
    Hyperthermia consists in raising the temperature above the physiological level to obtain a more efficient therapy. Hyperthermia is defined by a temperature rise to 39 ºC – 45 ºC. Celsius 42 local hyperthermia aims to achieve an ideal thermic dose in the tumor (either superficial or deep), without exceeding the tolerance limits of the normal adjacent tissue. Local hyperthermia is applied externally and non-invasively through 2 active electrodes which emit an electromagnetic energy directed to the treatment site.

  • Pathologies
    The Local Hyperthermia Celsius TCS device can be used alone or in combination with chemotherapy and/or radiotherapy in order to obtain a more effective treatment for people with cancer, whether at initial or advanced stages of the disease. The equipment is intended to be used in any type of solid tumor, namely:
    • Cervix
    • Brain
    • Head and neck
    • Lung
    • Melanoma
    • Breast
    • Bladder
    • Rectum
    • Esophagus
    • Pelvis

  • Technology
    • Selectivity
      One important difference between healthy cells and cancer cells is their electric charge: healthy cells have a positive charge inside and a negative charge on the outside; cancer cells have a negative charge inside and a positive charge on the outside, meaning their electric charge is inverse to that of a healthy cell.
      The electric charge defines the cell's voltage. A healthy cell can have a voltage up to +70mV, while a cancer cell is up to -30mV. The ions distribution (NA, H, K, Ca, and CI) is also dependent on the electric charge of each cell.
      The composition of extracellular fluids is different between each other. Each extracellular fluid reacts differently to external stimuli, such as frequency absorption. The extracellular fluid around the healthy cell absorbs mainly frequencies of 100MHz, while the extracellular fluid of cancer cells absorbs frequencies between 10 to 15MHz.
      To sum up, when the frequency (13.56MHz from the Celsius TCS device) is transmitted inside the body, between the 2 electrodes if applied, the result is a selective effect on the extracellular fluid of the cancer cells. The extracellular fluid around the cancer cells will begin to oscillate with a resonance of 13.56MHz (13.56 million cycles per second).
      This high oscillation frequency generates a selective warm-up of the tumor in the extracellular space. The generated heat is transferred through the extracellular space, connecting the ions and reaching the intracellular space. The temperature difference between the exterior and the interior of the cell affects the metabolism and blocks it, causing the protein denaturation of the cancer cells. At the same time, the electroosmotic effects increase the water pressure in the cytoplasm, which destabilizes the cellular membrane.
    • Effect of the electromagnetic field
      Cancer cells have a lower electric resistance, a higher dielectric constant and a higher negative polarization. The Celsius TCS device creates a high and homogeneous electric field between the electrodes, when applied. Due to the low electric resistance of the tumor, the electric current flows intensely through its cellular membrane, destabilizing it.
    • Capillary exchanges
      The heat transferred to the tumor tissue also affects the adjacent healthy tissue partially. The healthy tissue can dissipate heat easily, improving the blood flow. This cannot be achieved by the tumor tissue due to its lack of thermic regulation capability caused by the absence of a muscular layer in their blood vessels. This "generated" heat reinforces then the selective effect of hyperthermia and leads to the denutrition and deoxygenation of the cancer cells, resulting in the interference of significant metabolic processes of cellular division.

  • Contraindications
    Hyperthermia with Celsius TCS is not indicated in:
    • Patients with bone marrow transplantation;
    • Individuals with coronary bypass and its electrodes;
    • Individuals with metallic prosthesis placed near the treatment site of the tumor.

  • Reference in the application of hyperthermia:
    Dr. António Moreira Pinto, Medical Oncology Specialist, Head of Hyperthermia Treatment at CUF Porto Hospital with the Celsius 42 device.

  • Bibliography
    1 M.R. Horsman, J. Overgaard. Hyperthermia: a Potent Enhancer of Radiotherapy. Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark. Clinical Oncology (2007) 19: 418-426.
    2 J. Van der Zee, Z. Vujascovic, M. Kondo & T. Sugahara. The Kadota Fund International Forum 2004 – Clinical group consensus. International Journal of Hyperthermia, Marzo 2008; 24 (2): 111-122
    3 International Collaborative Hyperthermia Group: Vernon CC, Hand JW, Field SB, Machin D, Whaley JB, Van der Zee J, Van Putten WLJ, Van Rhoon GC, Van Dijk JDP, Gonza´lez Gonza´lez D, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials. Int J Radiat Oncol Biol Phys 1996;35:731–744.
    4 Jacoba van der Zee, Dionisio González, Gerard C van Rhoon, Jan D P van Dijk, Wim L J van Putten, Augustinus A M Hart, for the Dutch Hyperthermia Group. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. The Lancet, Vol 355, April 2000.
    5 Franckena M, Stalpers L.J.A., Koper P.C.M. Wiggenraad R.G.J. Hoogenraad W.J. Van der Zee J., Long term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int. J. Radiation Oncology Biol. Phys. 70, 4, 1176 - 1182. 2008.
    6 Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM.: Int Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology., J Hyperthermia 1996 Jan;12(1):3-20
    7 Issels R, Lindner L, Mella O, Kuhlencordt M, Hohenberger P, Abdel-Rahman S, et al.: Risk of early progression in patients with high-risk tissue sarcomas: Results of the Phase III randomized prospective trial of neoadjuvant chemotherapy with or without regional Hyperthermia (EORTC - ESHO Intergroup Trial)